Open an account

2Seventy Bio

TSVT · NASDAQ

Price unavailable right now.

No price history for this range.

About TSVT

2seventy Bio, Inc. operates as cell and gene therapy company. The company is headquartered in Cambridge, Massachusetts. The Company, together with Bristol-Myers Squibb Company (BMS), is delivering the United States Food and Drug Administration (FDA) approved CAR T therapy in multiple myeloma, Abecma, to patients in the United States. Abecma is its B cell maturation antigen (BCMA)-targeted CAR T cell therapy for multiple myeloma, in collaboration with BMS. ABECMA is a BCMA-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Abecma uses a lentiviral vector (LVV) to deliver a chimeric antigen receptor (CAR), with the potential to program a patient’s own T cells to recognize the plasma cell specific BCMA, a protein on the cell surface.

Employees
65
Headquarters
Cambridge, Massachusetts
Listed
Oct 18, 2021
Sector
Health Care
Industry
Biotechnology
Website
2seventybio.com

TSVT key statistics

This section is temporarily unavailable. Refresh to try again.

TSVT earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 46.1% on average.

  1. Q1 FY23: reported -$1.08 per share against an estimate of -$1.22
  2. Q2 FY23: reported -$0.83 per share against an estimate of -$1.09
  3. Q3 FY23: reported -$1.00 per share against an estimate of -$1.05
  4. Q4 FY23: reported -$1.11 per share against an estimate of -$1.01
  5. Q1 FY24: reported -$1.01 per share against an estimate of -$0.8284
  6. Q2 FY24: reported $0.45 per share against an estimate of -$0.6608
  7. Q3 FY24: reported -$0.19 per share against an estimate of -$0.246
  8. Q4 FY24: reported -$0.37 per share against an estimate of -$0.2703

TSVT news

  • Press releaseBusiness Wire

    2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb

  • Press releasePRNewswire

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BHLB, TSVT, RDFN on Behalf of Shareholders

  • Press releasePRNewswire

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BHLB, TSVT, RDFN on Behalf of Shareholders

  • Press releaseBusiness Wire

    2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT

  • Press releaseBusiness Wire

    2seventy bio Reports Fourth Quarter and Full Year 2024 Financial Results

  • Press releasePRNewswire

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDUS, NDOI, TSVT, RDFN on Behalf of Shareholders

  • Press releaseBusiness Wire

    2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT

  • Press releasePRNewswire

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TSVT, BRDG, GB on Behalf of Shareholders

Similar companies

Companies in the same industry as 2Seventy Bio

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.